HIV-associated neurocognitive disorders: A changing pattern

Future Neurology

Volumn 6, Issue 1, 2011, Pages 81-95

  Simioni, Samanta ^a   Cavassini, Matthias ^a   Annoni, Jean Marie ^b   Hirschel, Bernard ^b   Du Pasquier, Renaud A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

combination antiretroviral therapy neurotoxicity; combination antiretroviral therapy penetration; HIVassociated neurocognitive disorder; neurodegeneration; neuroinflammation; neuroprotective drug

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BIOLOGICAL MARKER; CPI 1189; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LEXIPAFANT; LITHIUM; MEMANTINE; N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; NIMODIPINE; PEPTIDE T; PLACEBO; RITONAVIR; SELEGILINE; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG RESPONSE; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 78650645395     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.10.76     Document Type: Review

References (91)

1. Sacktor N, Lyles RH, Skolasky R et al.: HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-1998. Neurology 56(2), 257-260 (2001).
2. Johnson RT: Immunodeficiency virus. In: Viral Infections of the Nervous System (2nd Edition). Johnson RT (Ed.). Lippincott-Raven, PA, USA, 287-313 (1998).
3. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 41(6), 778-785 (1991).
4. Antinori A, Arendt G, Becker JT et al.: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18), 1789-1799 (2007).
5. McArthur JC: HIV dementia: an evolving disease. J. Neuroimmunol. 157(1-2), 3-10 (2004).
6. Sacktor N, McDermott MP, Marder K et al.: HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 8(2), 136-142 (2002).
7. Cysique LA, Maruff P, Brew BJ: Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol. 10(6), 350-357 (2004).
8. Simioni S, Cavassini M, Annoni JM et al.: Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24(9), 1243-1250 (2010).
9. Hinkin CH, Castellon CA, Levine AJ, Barclay TR, Singer EJ: Neurocognition in individuals coinfected with HIV and hepatitis C. J. Addict. Dis. 27(2), 11-17 (2008).
10. Parsons TD, Tucker KA, Hall CD et al.: Neurocognitive functioning and HAART in HIV and hepatitis C virus coinfection. AIDS 20(12), 1591-1595 (2006).
11. Brew BJ: Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18(Suppl. 1), S75-S78 (2004).
12. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ: Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13(10), 1249-1253 (1999).
13. Stoff DM, Khalsa JH, Monjan A, Portegies P: Introduction: HIV/AIDS and aging. AIDS 18(Suppl. 1), S1-S2 (2004).
14. Valcour V, Shikuma C, Shiramizu B et al.: Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 63(5), 822-827 (2004).
15. Lopardo GD, Bissio E, Iannella Mdel C, Crespo AD, Garone DB, Cassetti LI: Good neurocognitive performance measured by the International HIV Dementia Scale in early HIV-1 infection. J. Acquir. Immune Defic. Syndr. 52(4), 488-492 (2009).
16. Cole MA, Margolick JB, Cox C et al.: Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology 69(24), 2213-2220 (2007).
17. Cysique LA, Maruff P, Brew BJ: Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 66(9), 1447-1450 (2006).
18. Robertson KR, Smurzynski M, Parsons TD et al.: The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21(14), 1915-1921 (2007).
19. Sevigny JJ, Albert SM, McDermott MP et al.: An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch. Neurol. 64(1), 97-102 (2007).
20. Grant I, Atkinson JH, Hesselink JR et al.: Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann. Intern. Med. 107(6), 828-836 (1987).
21. Heaton RK, Grant I, Butters N et al.: The HNRC 500 - neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J. Int. Neuropsychol. Soc. 1(3), 231-251 (1995).
22. McArthur JC, Steiner S, Sacktor N, Nath A: Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann. Neurol. 67(6), 699-714 (2010).
23. Alexaki A, Liu Y, Wigdahl B: Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6(5), 388-400 (2008).
24. Cherner M, Masliah E, Ellis RJ et al.: Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59(10), 1563-1567 (2002).
25. Churchill MJ, Wesselingh SL, Cowley D et al.: Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann. Neurol. 66(2), 253-258 (2009).
26. Koutsilieri E, ter Meulen V, Riederer P: Neurotransmission in HIV associated dementia: a short review. J. Neural. Transm. 108(6), 767-775 (2001).
27. Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5(1), 69-81 (2005).
28. Rajawat YS, Bossis I: Autophagy in aging and in neurodegenerative disorders. Hormones (Athens) 7(1), 46-61 (2008).
29. Nguyen TP, Soukup VM, Gelman BB: Persistent hijacking of brain proteasomes in HIV-associated dementia. Am. J. Pathol. 176(2), 893-902 (2010).
30. Anthony IC, Bell JE: The neuropathology of HIV/AIDS. Int. Rev. Psychiatry. 20(1), 15-24 (2008).
31. Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G: Neurodegeneration and ageing in the HAART era. J. Neuroimmune Pharmacol. 4(2), 163-174 (2009).
32. Guillemin GJ, Kerr SJ, Brew BJ: Involvement of quinolinic acid in AIDS dementia complex. Neurotox. Res. 7(1-2), 103-123 (2005).
33. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE: Monocyte chemoattractant protein-I plays a dominant role in the chronic inflammation observed in Alzheimers disease. Brain Pathol. 19(3), 392-398 (2009).
34. Bjorkqvist M, Wild EJ, Thiele J et al.: A novel pathogenic pathway of immune activation detectable before clinical onset in Huntingtons disease. J. Exp. Med. 205(8), 1869-1877 (2008).
35. Town T, Laouar Y, Pittenger C et al.: Blocking TGF-b-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14(6), 681-687 (2008).
36. Okun MS, DeLong MR, Hanfelt J, Gearing M, Levey A: Plasma testosterone levels in Alzheimer and Parkinson diseases. Neurology 62(3), 411-413 (2004).
37. Valcour VG, Shikuma CM, Watters MR, Sacktor NC: Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS 18(Suppl. 1), S79-S86 (2004).
38. An SF, Giometto B, Groves M et al.: Axonal damage revealed by accumulation of b-APP in HIV-positive individuals without AIDS. J. Neuropathol. Exp. Neurol. 56(11), 1262-1268 (1997).
39. Rempel HC, Pulliam L: HIV-1 Tat inhibits neprilysin and elevates amyloid b. AIDS 19(2), 127-135 (2005).
40. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL: Brain deposition of b-amyloid is a common pathologic feature in HIV positive patients. AIDS 19(4), 407-411 (2005).
41. Ances BM, Christensen JJ, Teshome M et al.: Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB. A case-control study. Neurology 75(2), 111-115 (2010).
42. Shaw LM, Vanderstichele H, Knapik-Czajka M et al.: Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects. Ann. Neurol. 65(4), 403-413 (2009).
43. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L: CSF amyloid b42 and tau levels correlate with AIDS dementia complex. Neurology 65(9), 1490-1492 (2005).
44. Clifford DB, Fagan AM, Holtzman DM et al.: CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 73(23), 1982-1987 (2009).
45. Ellis RJ, Seubert P, Motter R et al.: Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC). Neurosci. Lett. 254(1), 1-4 (1998).
46. Green AJE, Giovannoni G, Hall-Craggs MA, Thompson EJ, Miller RF: Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex. Transm. Infect. 76(6), 443-446 (2000).
47. Gisslen M, Krut J, Andreasson U et al.: Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 9, 63 (2009).
48. Brew BJ: Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin. Infect. Dis. 50(6), 930-932 (2010).
49. Letendre S, Marquie-Beck J, Capparelli E et al.: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65(1), 65-70 (2008).
50. Cysique LA, Vaida F, Letendre S et al.: Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73(5), 342-348 (2009).
51. Marra CM, Zhao Y, Clifford DB et al.: Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23(11), 1359-1366 (2009).
52. Tozzi V, Balestra P, Salvatori MF et al.: Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52(1), 56-63 (2009).
53. Langford TD, Letendre SL, Marcotte TD et al.: Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16(7), 1019-1029 (2002).
54. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F: Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J. Neurovirol. 11(Suppl. 3), 16-22 (2005).
55. Riedel DJ, Pardo CA, McArthur J, Nath A: Therapy insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat. Clin. Pract. Neurol. 2(10), 557-565 (2006). (Pubitemid 44445811)
56. Johnson T, Nath A: Neurological complications of immune reconstitution in HIV-infected populations. Ann. NY Acad. Sci. 1184, 106-120 (2010).
57. McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C: Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 72(9), 835-841 (2009).
58. Kohler JJ, Lewis W: A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ. Mol. Mutagen. 48(3-4), 166-172 (2007).
59. Piccinini M, Rinaudo MT, Anselmino A et al.: The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther. 10(2), 215-223 (2005).
60. Schweinsburg BC, Taylor MJ, Alhassoon OM et al.: Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J. Neurovirol. 11(4), 356-364 (2005).
61. Chang L, Yakupov R, Nakama H, Stokes B, Ernst T: Antiretroviral treatment is associated with increased attentional load-dependent brain activation in HIV patients. J. Neuroimmune Pharmacol. 3(2), 95-104 (2008).
62. Chang L, Ernst T, Leonido-Yee M et al.: Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 53(4), 782-789 (1999).
63. Ances BM, Roc AC, Korczykowski M, Wolf RL, Kolson DL: Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients. J. Neurovirol. 14(5), 418-424 (2008).
64. Cysique LA, Maruff P, Brew BJ: Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch. Neurol. 61(11), 1699-1704 (2004).
65. Robertson KR, Su Z, Margolis DM et al.: Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74(16), 1260-1266 (2010).
66. Clifford DB: Therapeutic conundrum: AIDS therapies may be double-edged swords. Neurology 74(16), 1248-1249 (2010).
67. El-Sadr WM, Lundgren JD, Neaton JD et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group: CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355(22), 2283-2296 (2006).
68. Winston A, Duncombe C, Li PCK et al.: Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin. Infect. Dis. 50(6), 920-929 (2010).
69. Cysique LA, Murray JM, Dunbar M, Jeyakumar V, Brew BJ: A screening algorithm for HIV-associated neurocognitive disorders. HIV Med. 11(10), 642-649 (2010).
70. Power C, Selnes OA, Grim JA, McArthur JC: HIV Dementia Scale: a rapid screening test. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8(3), 273-278 (1995).
71. Smith CA, van Gorp WG, Ryan ER, Ferrando SJ, Rabkin J: Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J. Acquir. Immune Defic. Syndr. 33(1), 116-118 (2003).
72. Bottiggi KA, Chang JJ, Schmitt FA et al.: The HIV dementia scale: predictive power in mild dementia and HAART. J. Neurol. 260(1-2), 11-15 (2007).
73. Rumbaugh JA, Steiner J, Sacktor N, Nath A: Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur. HIV Ther. 2(3), 271-280 (2008).
74. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 49(1), 142-146 (1997).
75. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in human immunodeficiency virus-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 50(3), 645-651 (1998).
76. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K: Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 54(1), 233-235 (2000).
77. Schifitto G, Zhang J, Evans SR et al.: A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 69(13), 1314-1321 (2007). (Pubitemid 47482445)
78. Evans SR, Yeh TM, Sacktor N et al.: Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin. Trials. 8(6), 437-446 (2007). (Pubitemid 350305218)
79. Schifitto G, Yiannoutsos CT, Ernst T et al.: Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 73(23), 1942-1944 (2009).
80. Letendre SL, Woods SP, Ellis RJ et al.: Lithium improves HIV-associated neurocognitive impairment. AIDS 20(14), 1885-1888 (2006).
81. Schifitto G, Zhong J, Gill D et al.: Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J. Neurovirol. 15(2), 176-186 (2009).
82. Navia BA, Dafni U, Simpson D et al.: A Phase I-II trial of nimodipine for HIV-related neurologic complications. Neurology 51(1), 221-228 (1998).
83. Heseltine PN, Goodkin K, Atkinson JH et al.: Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch. Neurol. 55(1), 41-51 (1998).
84. Schifitto G, Sacktor N, Marder K et al.: Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology 53(2), 391-396 (1999).
85. Clifford DB, McArthur JC, Schifitto G et al.: A randomized clinical trial of CPI-1189 for HIV-associated cognitive- motor impairment. Neurology 59(10), 1568-1573 (2002).
86. Schifitto G, Navia BA, Yiannoutsos CT et al.: Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 21(14), 1877-1889 (2007).
87. Zhao Y, Navia BA, Marra CM et al.: Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin. Trials 11(1), 59-67 (2010).
88. Alisky JM: Could cholinesterase inhibitors and memantine alleviate HIV dementia? J. Acquir. Immune Defic. Syndr. 38(1), 113-114 (2005).
89. Koutsilieri E, Czub S, Scheller C et al.: Brain choline acetyltransferase reduction in SIV infection. An index of early dementia? Neuroreport 11(11), 2391-2393 (2000).
90. When To Start Consortium; Sterne JA, May M, Costagliola D et al.: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373(9672), 1352-1363 (2009).
91. Letendre S, Ellis RJ, Deutsch R et al.; for the CHARTER Group: Correlates of time-to-loss-of-viral-response in CSF and plasma in the CHARTER Cohort. Presented at: 17th Conference on Retroviruses and Opportunistic Infections (CROI). San Francisco, CA, USA, 16-19 February 2010.